Regadenoson is a coronary vasodilator used in radionuclide myocardial perfusion imaging (MPI). Manufactured by Astellas and FDA approved April 10, 2008.
- Mechanism
- Curator reviewed
Regadenoson is an selective low-affinity (Ki= 1.3 µM) A2A receptor agonist that mimics the effects of adenosine in causing coronary vasodilatation and increasing myocardial blood flow. It is a very weak agonist of the A1 adenosine receptor (Ki > 16.5 µM). Furthermore, it has negligible affinity to A2B and A3 adenosine receptors. Regadenoson is undergoing trials for use in pharmacological stress tests. Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.
- Primary indication
- Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)Curator reviewed · 1 structured indication
- Formula / weight
- C15H18N8O5 · 390.354 g/mol (avg)
- First approval
- United States, 2008 · European Union, 2020
- Code names
- CVT-3146
- Brand names
Resolves to
LZPZPHGJDAGEJZ-AKAIJSEGSA-NSMILESCNC(=O)C1=CN(N=C1)C1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(N)=N1What you can answer from here — as of August 30, 2026
Which drugs share a target with Regadenoson, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account